Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Chemotherapy - cytotoxic

55 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Diagnostic

    Leukemia

    ECOGHEMEAI141

    05/10/2016

    Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

    Other

    Multiple Myeloma

    VICCHEM1470

    11/05/2014

    Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

    Prevention

    Leukemia
    Lymphoma
    Myelodysplastic Syndrome
    Pediatric Leukemia
    Pediatric Lymphoma

    VICCPED1627

    11/17/2016

    Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis

    Treatment

    Lung
    Small Cell

    VICCTHO1629

    11/17/2016

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin plus Etoposide with or without Atezolizumab (ANTI−PD-L1 Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

    Treatment

    Breast
    Head/Neck
    Lung
    Miscellaneous

    VICCPHI15100

    11/04/2016

    A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

    Treatment

    Rectal

    VICCGI1601

    10/31/2016

    A Phase I Trial of MEK Inhibitor Trametinib in Combination with Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of Rectal Cancers

    Treatment

    Colon
    Rectal

    VICCGI1667

    10/18/2016

    MM-151-06-12-04: A Phase 1 Study Combining MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

    Treatment

    Leukemia

    VICCBMT1617

    10/11/2016

    The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

    Treatment

    Leukemia

    VICCBMT1652

    09/30/2016

    VICCBMT1652 - A Phase 1, Multicenter, Open-Label, Dose-Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion with Subcutaneous Recombinant Human IL-2 (RHIL- 2) in Adults with Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

    Treatment

    Leukemia

    VICCHEM1654

    09/09/2016

    An Open-Label, Multi-Center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-Like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who are Eligible for Standard Induction and Consolidation Chemotherapy

    Treatment

    Myelodysplastic Syndrome
    Pediatric Leukemia

    COGAAML1531

    08/23/2016

    Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

    Treatment

    Sarcoma

    COGARST1431

    08/18/2016

    A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

    Treatment

    Esophageal

    VICCGI15146

    08/05/2016

    A Multicenter, Randomized, Open-label Study in Patients with Esophageal Cancer Refractory or Intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs

    Treatment

    Leukemia

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Treatment

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    VICCPED1537

    04/28/2016

    T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Treatment

    Lung
    Non Small Cell

    ECOGTHOS1403

    04/26/2016

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

    Treatment

    Breast

    VICCBRE1587

    04/05/2016

    An Open-Label, First -in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

    Treatment

    Breast

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Treatment

    Leukemia

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    Bladder

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    Breast - Female

    VICCBRE14101

    12/04/2015

    Phase I/II Study of BYL719 and Nab-Paclitaxel in Patients with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

    Treatment

    Multiple Myeloma

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Treatment

    Lymphoma

    VICCHEM14125

    11/13/2015

    A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

    Treatment

    Colon
    Esophageal
    Gastric/Gastroesophageal
    Liver
    Pancreatic
    Rectal

    VICCGIP1536

    10/26/2015

    A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Lung

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti−PDL1 Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine For PD L1-Selected Chemotherapy-Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

    Treatment

    Breast

    ECOGBREEA1131

    09/24/2015

    A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

    Treatment

    Bladder
    Urologic

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    Pediatric Lymphoma

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

    Treatment

    Lung
    Small Cell

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    Multiple Myeloma

    VICCHEM1526

    07/01/2015

    A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-Refractory to Previous Therapies

    Treatment

    Gynecologic
    Ovarian

    VICCGYN1492

    06/16/2015

    A Randomized, Open-Label Study Comparing the Combination of YONDELIS? and DOXIL?/CAELYX? With DOXIL?/CAELYX? Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Treatment

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    Lung
    Non Small Cell

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    Pediatric Lymphoma

    COGANHL12P1

    10/20/2014

    A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

    Treatment

    VICCPHI1436

    08/18/2014

    A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

    Treatment

    Leukemia

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    Pancreatic

    VICCGI1370

    12/30/2013

    A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

    Treatment

    Neuroendocrine
    Pancreatic

    VICCGI1250

    04/09/2013

    A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

    Treatment

    Leukemia

    VICCHEM1294

    02/25/2013

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

    Treatment

    Lymphoma

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

    Treatment

    Breast

    CTSUNSABPBREB-47-M

    04/26/2012

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

    Treatment

    Liver

    CTSUGI80702-M

    05/05/2011

    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

    Treatment

    Non Small Cell

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Treatment

    Liver

    CTSUGIC80802-M

    12/07/2010

    Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

    Treatment

    Lung

    ECOGTHO4508-M

    12/07/2010

    Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

    Treatment

    Breast

    CTSUBREC40603-M

    12/07/2010

    Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

    Treatment

    Head/Neck

    ECOGHNE1305-M

    02/11/2009

    A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

    Treatment

    Prostate

    CTSUUROC90203-M

    11/05/2007

    A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

    Treatment

    Non Small Cell

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor